Gestational diabetes. Diabetes mellitus in pregnancy, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Zinc capsule (Donyayeh Behesht Pharmaceutical Company, Tehran, Iran), 30 mg, once a day for 6 weeks orally. Intervention 2: Control group: Placebo capsule (Barij Es
Sponsors
Arak University of Medical Sciences
Kashan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Pregnant women aged 18-40 years diagnosed with gestational diabetes mellitus at 24-28 weeks' gestation
Exclusion criteria
Exclusion criteria: Taking zinc supplements Premature preterm rupture of membrane Placenta abruption Pre-eclampsia Eclampsia Chronic hypo- and hypothyroidism The use of substitute treatments including hormone or vitamin supplements Complete bed rest (CBR) Intra uterine fetal death (IUFD) Preterm delivery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insulin. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Eliza.;Insulin resistance. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Calculation with HOMA formula.;Hs-CRP. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Eliza.;Newborns PPAR-gamma. Timepoint: Cord blood of newborns of women with GDM at delivery time. Method of measurement: PCR-RT. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting blood sugar. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;VLDL-cholesterol. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;LDL-cholesterol. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Newborns' weight. Timepoint: The first 24 h after birth. Method of measurement: Scale.;Newborn length. Timepoint: The first 24 h after birth. Method of measurement: Girth measuring tape.;Newborn head circumference. Timepoint: The first 24 h after birth. Method of measurement: Girth measuring tape.;Polyhydramnios. Timepoint: After 6 weeks of intervention. Method of measurement: Sonography.;Newborns glucose transporter 1 (GLUT1). Timepoint: Cord blood of newborns of women with GDM at delivery time. Method of measurement: PCR-RT. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZatollah Asemi
Kashan University of Medical Sciences
Outcome results
None listed